688235:SSEBeOne Medicines Ltd. Class A Analysis

BeOne Medicines AG is reporting a striking revenue surge, with Q4 2025 sales of $1.5 billion and a projected full‑year 2026 revenue of $5.3 billion – a 33%‑40% jump year‑over‑year, underscoring its rapid growth in the oncology market. Operating margins have expanded to 12.35% and gross margins sit at an impressive 87.5%, indicating strong pricing power and efficient cost control. However, the stock trades at a trailing PE of 175x versus an industry average of 26x, and a discounted cash‑flow fair value of just $21, suggesting the market has priced in far higher expectations than fundamentals support. The technical picture is mixed: the price of CNY 231.3 sits below the 20‑day, 50‑day, and 200‑day SMAs, the MACD is bearish, and RSI is at 33, hinting at short‑term oversold conditions, while volume is increasing and beta remains low at 0.23, limiting broader market volatility exposure. With a high 30‑day volatility of nearly 40% and a max drawdown close to 30%, downside risk remains material, especially if upcoming earnings miss consensus. The company carries no dividend and a modest debt‑to‑equity profile, while its book‑to‑price ratio (<1) suggests the balance sheet is relatively sound.